The p53 gene family of transcription factors has a role in the regulation of differentiation, and proliferation of somatic and stem cells, and it also has an important role in tumor suppression.^[@bib1],\ [@bib2]^ Emerging evidence suggests that while p73 share many functional properties with p53, it also has distinct and unique biological functions in processes such as neurogenesis and embryonic development. The *TP73* gene exhibits a dual nature, which relies on the existence of TA and DNp73 variants. The TA proteins are transactivation competent,^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ whereas the DN isoforms can have dominant-negative function towards p53 and TAp73,^[@bib8],\ [@bib9]^ acting as a major survival factor in postmitotic neurons,^[@bib10]^ or transactivating target genes in a cell context-dependent manner.^[@bib7],\ [@bib11]^ Thus, the TA/ΔN differential expression is crucial for determining p73 function. This regulation can operate at transcriptional^[@bib12]^ or post-transcriptional levels.^[@bib13],\ [@bib14],\ [@bib15]^

The compilation of work regarding p73 function in neural development indicates that p73 has a complex multifunctional role in this process. There is strong evidence demonstrating TAp73 induction of neuronal differentiation. In this regard, the hippocampal defects also present in the TAp73−/−-specific mice, together with TAp73 regulation of miR-34a, support TAp73 function in neuronal differentiation.^[@bib16]^ Furthermore, overexpression of TAp73 induces neurite outgrowth and expression of neuronal markers in neuroblastoma and pheochromocytoma cell lines^[@bib3],\ [@bib17]^ and spontaneous differentiation of oligodendrocytes.^[@bib18]^ In contrast, recent reports have demonstrated p73 requirement, mainly TAp73, in the maintenance of neural stem/progenitor cells (NSC/NPC) self-renewal,^[@bib19]^ where it blocks premature differentiation of embryonic neural progenitor cells (NPCs) in a p53-independent manner.^[@bib20],\ [@bib21]^

It is reasonable to consider that p73 would execute some of its multiple functions through the transcriptional regulation of cell context-specific target genes. In this regard, previous work using the human chronic myeloid leukemia cell line, K562, with ectopic ΔNp73 expression^[@bib7]^ revealed tripartite motif protein 32 (TRIM32) as a putative p73 transcriptional target. Furthermore, published *in silico* analyses have also proposed TRIM32 as a TAp73 target.^[@bib22],\ [@bib23]^

TRIM32 belongs to the TRIM-NHL family^[@bib24]^ and it has been involved in NPCs\' regulation of differentiation and self-renewal during mouse embryonic brain development.^[@bib25],\ [@bib26]^ TRIM32 is asymmetrically distributed in NPC, and segregates with the daughter cell that undergoes neuronal differentiation.^[@bib26]^ TRIM32 is retained in the cytoplasm of dividing progenitors and it is translocated to the nucleus to initiate neuronal differentiation.^[@bib25]^ TRIM32 also regulates skeletal muscle stem cell differentiation^[@bib27]^ as well as RAR*α*-induced differentiation of acute promyelogenous leukemic cells.^[@bib28]^ Furthermore, TRIM32 increased expression has been associated with enhanced epidermal carcinogenesis,^[@bib29]^ cell growth and migration,^[@bib30]^ linking TRIM32 altered regulation to the oncogenic process.

At the molecular level, TRIM32 has two functions:it mediates the polyubiquitination of c-Myc and it binds to the protein Argonaute-1, thereby increasing the activity of differentiation-inducing micro-RNAs like Let-7a.^[@bib26],\ [@bib31]^ Nevertheless, the mechanisms that regulate TRIM32 expression remain unclear, and while TRIM32 regulation via p73 has been predicted by *in silico* analysis,^[@bib22]^ experimental evidence is still lacking.

In this article, we demonstrate for the first time that TRIM32 expression is differentially regulated by p73 at the transcriptional level. Although TAp73 activates TRIM32 expression, ΔNp73 efficiently represses TAp73 transactivation of this promoter. TRIM32 in turn, binds to TAp73, promotes its ubiquitination in a RING-finger-dependent manner and degrades it. Furthermore, TRIM32 overexpression can repress TAp73 transcriptional activation of the p21^Cip^ promoter. Thus, we have identified a novel regulatory feedback loop between TP73 and TRIM32, similar to that of p53 and MDM2.

Results
=======

P73 expression modulates TRIM32 levels
--------------------------------------

Previous genome-wide expression analysis^[@bib7]^ revealed significant downregulation of the neuronal fate determinant TRIM32, suggesting that it could be a p73 transcriptional target. To address this, we first examined whether constitutive expression of TAp73 and/or DNp73 could modulate TRIM32 expression in immortalized mouse NPC C17.2,^[@bib32]^ and in the mouse neuroblastoma cells, N2a ([Figures 1a and b](#fig1){ref-type="fig"}). TAp73 transfection resulted in a significant upregulation of TRIM32 expression in the case of TAp73*α* in C17.2 and TAp73*β* in N2a, by real-time quantitative PCR (qRT-PCR) analysis. Western blot analysis of C17.2 confirmed these results showing a moderate (threefold) but a statistically significant increase in TRIM32 protein level upon ectopic expression of TAp73*α* ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}, *P*\<0.005). DNp73 transfection alone had either no effect or decreased TRIM32 basal levels. Interestingly, when DNp73 and TAp73 were present at a 1 : 1 ratio, TRIM32 mRNA expression was repressed, indicating a dominant-negative effect of DNp73. Even in the presence of 10-fold levels of TAp73, DNp73 efficiently inhibits TAp73-induced upregulation ([Figure 1b](#fig1){ref-type="fig"} and [Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). Similar results were obtained in the murine embryonic stem cell line E14TG2a ([Supplementary Figure 1B](#sup1){ref-type="supplementary-material"}). Both isoforms of TAp73 (*α* and *β*) can regulate TRIM32 expression but their effect depends on the cell context. At the RNA level, TAp73*α* seems to have a more general and consistent effect than TAp73*β*. Therefore, we used TAp73*α* throughout this this study.

To demonstrate the correlation between TAp73 and TRIM32 expression in a physiological *in vitro* context, we used NPC cultured with the neurosphere (NS) assay,^[@bib33]^ as TRIM32 expression and regulation has been previously described in these cultures.^[@bib25],\ [@bib26]^ TAp73 and TRIM32 expression was analyzed by confocal microscopy in NS cultures obtained from olfactory bulbs (OBs) of wild-type (WT) E14.5 embryos. NPCs in the WT cultures presented low, but detectable, TRIM32. Interestingly, TRIM32 levels were lower in cells where TAp73 expression was mostly cytoplasmic, suggesting low or no TAp73 transcriptional activity ([Figure 1c](#fig1){ref-type="fig"}, white arrows). However, in cells with nuclear TAp73, TRIM32 expression was enhanced ([Figure 1c](#fig1){ref-type="fig"}, yellow arrows). Moreover, in those cells, TAp73 and TRIM32 colocalized within the nucleus.

We next analyzed endogenous TRIM32 levels on NS cultures from Trp73−/− mice (p73 knockout (KO) from now on).^[@bib21]^ Comparative analysis by qRT-PCR and western blot revealed that TRIM32 expression levels were lower in p73KO cultures than in WT cells ([Figures 1d and e](#fig1){ref-type="fig"}, respectively). Consistently, confocal microscopy analysis showed that while TRIM32 expression in WT-NS was low, but detectable in most of the cells, in the p73KO cultures, only few cells presented detectable TRIM32 expression ([Supplementary Figure 1C](#sup1){ref-type="supplementary-material"}). Altogether, these data support the idea that TAp73 could be a transcriptional regulator of TRIM32. Furthermore, we found that partial TAp73 knockdown resulted in slight, but significant, downregulation of TRIM32 levels in HEK293 cells ([Supplementary Figure 1D](#sup1){ref-type="supplementary-material"}).

P73 differentially regulates TRIM32 expression at the transcriptional level
---------------------------------------------------------------------------

A number of p53/p73-binding sites have been reported in mouse and human TRIM32 promoters by *in silico* analysis,^[@bib22]^ supporting the idea that TRIM32 could be a p73 transcriptional target. Consistently, *in silico* prediction of p53-responsive elements (p53REs) within the human TRIM32 locus using p53 Family Target Genes (FamTaG) database^[@bib34]^ unveiled four p53-binding sites in this gene, two of them located in the 5′-flanking region (at positions −1551 to −1514 and −115 to −84, relative to the transcription start site at exon 1), whereas the other two were within intron 1. Thus, to demonstrate that p73 regulation of TRIM32 was at the transcriptional level, a fragment of the human TRIM32 promoter (−1351 to +270) was amplified ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}) and subcloned into the pGL3-basic plasmid, generating the hTRIM32-luciferase (luc) reporter vector. This construct contains the p53RE identified in the proximal promoter (−115 to −84) ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}, red box). In the murine TRIM32 promoter, another p53RE has been described in this region, which is quite conserved in the human promoter ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}, orange box).

Transcriptional assays in C17.2 cells showed that TAp73*α*, but not the transcriptional-inactive mutant TAp73-292, significantly activated the hTRIM32-luc reporter, whereas p53 has no significant effect in this cell line ([Figure 2a](#fig2){ref-type="fig"}). To determine if this p73 function was limited to neural-like cells, transcriptional assays were performed in HCT116 human colon carcinoma cells, which have undetectable TRIM32 expression ([Supplementary Figure 3A](#sup1){ref-type="supplementary-material"}). TAp73, but not TAp73-292 nor DNp73, significantly activated the hTRIM32-luc reporter, demonstrating that this regulation was specific and not limited to neural-like cells ([Figure 2b](#fig2){ref-type="fig"}). TAp73*α*, but not TAP73*α*-292 or DNp73*α*, transactivates, but less efficiently, the commercially available (GeneCopoeia) murine TRIM32-luc promoter vector in the mouse cell lines, E14TG2a and C17.2 ([Supplementary Figures 3B and C](#sup1){ref-type="supplementary-material"}, respectively). Furthermore, transcriptional analysis with a mutant hTRIM32-luc, lacking the p53RE ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}), revealed a significant decrease in ectopic TAp73-induced activity ([Figure 2b](#fig2){ref-type="fig"}). Similar results were obtained in the C17.2 cell line ([Supplementary Figure 3D](#sup1){ref-type="supplementary-material"}). Altogether, our data demonstrate that TAp73 transcriptional activity over the TRIM32 promoter is specific and requires, at least in part, the p53RE. To address whether TAp73 could modulate TRIM32 promoter in the absence of endogenous p53, and to avoid TA *versus* DNp73 interactions, we used mouse embryonic fibroblasts deficient for both *TP53* and *TP73* genes (DKO MEFs). In these cells, both TAp73 and p53, but not DNp73, significantly transactivated the reporter, demonstrating that TRIM32 expression was regulated at the transcriptional level by these p53 family members ([Figure 2c](#fig2){ref-type="fig"}). To determine if DNp73 repression of TAp73-induced TRIM32 expression could be detected at the promoter level, we co-transfected DNp73 and TAp73 at various ratios in DKO MEFs and performed reporter assays. We observed a significant decrease of TAp73-induced promoter transactivation in the presence of increasing amounts of DNp73, even at \<1 : 1 ratio. This supports the prediction that DNp73 efficiently repress TAp73 transactivation of TRIM32 promoter ([Figure 2d](#fig2){ref-type="fig"}). Finally, to unequivocally demonstrate that TRIM32 was a direct transcriptional target of TA and DNp73, we performed chromatin immunoprecipitation (ChIP) assays. Immunoprecipitation with anti-HA antibody (lanes 1 and 2) showed that both ectopic TA and DN p73 bound directly to the predicted p53/p73-binding site of the TRIM32 promoter. Furthermore, endogenous p73 immunoprecipitated with anti-p73 in untransfected cells (lane 4) also bound directly to this site. Altogether, these data demonstrated, for the first time, that TRIM32 is a direct transcriptional target of TAp73 and that TA and DN p73 differentially regulate this gene.

P73 deficiency results in lower TRIM32 levels
---------------------------------------------

To corroborate that TA and ΔNp73 transcriptional regulation of TRIM32 promoter occurs under physiological conditions *in vitro* and *in vivo*, we sought to analyze the effect of p73 deficiency in differentiating NPC cultures and in the brain tissue of WT and p73KO mice.

TRIM32 is involved in the regulation of NPC differentiation during mouse embryonic brain development.^[@bib27]^ Thus, we analyzed whether p73 and TRIM32 expression kinetics correlated in a physiological and relevant system, such as the differentiation process of embryonic NPC ([Figure 3a](#fig3){ref-type="fig"}) and the effect of p73 deficiency on TRIM32 kinetics during this process ([Figure 3b](#fig3){ref-type="fig"}). TAp73 is significantly more abundant than DNp73 in NPCs.^[@bib21]^ TAp73 expression is upregulated early during the differentiation process and increases steadily up to 5 days *in vitro* (DIV)-DM. At 6 DIV, TAp73 suffers a slight decrease and then reaches its maximal expression at 8 DIV ([Figure 3a](#fig3){ref-type="fig"}, black bars). DNp73 is undetectable during the first days of differentiation, beginning to be expressed at 5 DIV-DM and then increasing steadily up to 8 DIV-DM ([Figure 3a](#fig3){ref-type="fig"}, dark gray bars). TRIM32 expression (light gray bars) correlates with the initial upregulation of TAp73 during the first differentiation days, reaching maximal levels at 5 DIV-DM. TRIM32 upregulation coincides with DNp73 lowest expression levels, from 1 DIV-5DIV. Later on, its expression decreases concurrently with DNp73 upregulation, despite the elevated levels of TAp73 (8 DIV), probably reflecting DNp73 repression of TAp73 activity. This expression kinetic is consistent with TA- and DN-p73 differential regulation of TRIM32.

Comparative analysis of TRIM32 expression in differentiating NPCs from WT and p73KO NS cultures revealed a significant decrease of TRIM32 levels in the absence of p73 at every stage analyzed ([Figure 3b](#fig3){ref-type="fig"}), highlighting the relevant role of TAp73 in TRIM32 upregulation during neuronal differentiation. Nevertheless, p73KO cultures express, and upregulate, TRIM32 during this process. Therefore, other p73-independent mechanisms are also regulating TRIM32 expression during NPC differentiation.

We next analyzed TRIM32 upregulation in individual cells in NPCs cultured under conditions supporting progressive neural differentiation and stained for TRIM32, and the neuronal marker, Tuj-1, after 24 h in culture (1 DIV-DM). At such early point of differentiation, WT cultures still showed detectable expression of TRIM32, with few cells beginning to express Tuj-1 presenting short lamellipodia and/or short unbranched processes ([Figure 3c](#fig3){ref-type="fig"}, upper left panel). In these cells, TRIM32 expression was mostly cytoplasmic, confirming the expected immature phenotype.^[@bib25]^ At this stage of differentiation, we only rarely detected cells with neurite extensions longer than 4 × their soma in WT cultures. In these cases, TRIM32 expression was stronger in the nucleus indicating a mature phenotype ([Figure 3](#fig3){ref-type="fig"}, upper right panel, arrow). The majority of the cells in the p73KO cultures presented lower TRIM32 levels than in WT cells ([Figure 3c](#fig3){ref-type="fig"}, lower panel). However, as published previously,^[@bib21]^ under identical mitotic culture conditions, we detected significantly higher number of Tuj-1-positive cells (2 *versus* 0.31%, *P*\<0.001) with long and branched neurite extensions, highlighting the premature neuronal differentiation detected in p73KO cultures ([Figure 3c](#fig3){ref-type="fig"}, lower panel, arrows). Strikingly, despite the lack of p73, all Tuj-1-positive cells, with neurite extensions, had enhanced TRIM32 expression (24% of this was exclusively nuclear, whereas 52% was nuclear and cytoplasmic), all congruent with a mature neuronal phenotype and supporting the essential role of TRIM32 in neuronal differentiation. These data confirm the existence of p73-independent mechanisms of TRIM32 regulation. Furthermore, it supports the idea that lack of p73 leads to premature embryonic NPCs\' differentiation *in vitro* and underlines the required role of TRIM32 in this process.

To confirm TRIM32 and TAp73 correlation in an *in vivo* context, we sought to study TRIM32 expression pattern in E14.5 embryo brains. This time coincides with the peak of mouse cortical neurogenesis, when TRIM32 is strongly expressed in the cortical plate and the ventricular zone, and colocalizes with the expression of Tuj-1.^[@bib26]^ qRT-PCR analysis of whole E14.5 brains demonstrated that, whereas p73KO E14.5 embryos expressed TRIM32, there was a significant reduction in total TRIM32 expression levels compared with WT ([Figure 4a](#fig4){ref-type="fig"}). This reduction in TRIM32 expression is also observed, albeit diminished, in the brains of P7 young mice ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). The gross anatomy of the cortex seems to be unaffected by the absence of p73, and neither neuronal differentiation *per se* seems to be strongly affected ([Figures 4b--d](#fig4){ref-type="fig"}). Furthermore, TRIM32 levels in the cortex seem to be normal, indicating that, as *in vitro*, there are p73-independent factors that ensure TRIM32 expression. Interestingly, TRIM32 levels were strongly reduced in the ventricular zone (VZ)/subventricular zone (SVZ) of p73KO animals ([Figure 4e](#fig4){ref-type="fig"}). These lower levels of TRIM32 in the VZ/SVZ correlate with the reduced amount of newly generated neurons (Tuj-1) in this region ([Figures 4f and g](#fig4){ref-type="fig"}), suggesting that p73 deficiency leads to TRIM32 downregulation affecting the population of NPCs that controls neurogenesis in the VZ/SVZ.

TRIM32 interacts and promotes p73 ubiquitination and degradation, impairing TAp73 transcriptional activity
----------------------------------------------------------------------------------------------------------

TRIM32 E3 ubiquitin ligase function^[@bib35]^ leads us to hypothesize the possible existence of a regulatory loop between TRIM32 and its regulator, p73. To address this point, we first investigated whether p73 and TRIM32 could physically interact *in vivo*. HEK293 cells were transiently transfected with plasmids encoding human myc-TRIM32, with or without HA-TAp73*α*, treated with the proteasome inhibitor MG132 and immunoprecipitated with antibodies against the ectopic ([Figure 5a](#fig5){ref-type="fig"}) or the endogenous ([Figure 5b](#fig5){ref-type="fig"}) p73. Myc-TRIM32 specifically interacted with both overexpressed HA-TAp73*α* and endogenous TAp73*α* ([Figure 5b](#fig5){ref-type="fig"}). Similar results were seen with murine HA-TRIM32 ([Supplementary Figure 5A](#sup1){ref-type="supplementary-material"}). We also detected interaction between transfected DNp73*α* and HA-TRIM32 in HEK293 cells ([Supplementary Figure 5B](#sup1){ref-type="supplementary-material"}), suggesting that TRIM32 can form a stable complex with TAp73*α* and DNp73*α*.

We next asked whether p73 was a substrate for TRIM32-mediated ubiquitination. HEK293 cells were transfected with HA-TAp73*α*, with or without TRIM32 and ubiquitin, and treated with MG132. In cells in which TRIM32-WT was coexpressed, p73 slower-migrating ubiquitin-modified bands were detected ([Figure 5c](#fig5){ref-type="fig"}). In contrast, these modified forms of p73 were absent in the presence of Δ-RING-TRIM32-MUT, lacking the RING-finger domain. Consistent results were obtained with murine-TRIM32 and TAp73 *α* and *β* ([Supplementary Figure 5C](#sup1){ref-type="supplementary-material"}) altogether, suggesting that TRIM32 can promote p73 ubiquitination in a RING-finger-dependent manner. To determine whether this interaction resulted in TAp73 degradation, we transfected HCT116 cells with HA-TAp73*α* with or without GFP-TRIM32 and analyzed HA-TAp73 expression at different time points after transfection. Ectopic TAp73 expression is progressively lost in the presence of overexpressed TRIM32 ([Supplementary Figure 5D](#sup1){ref-type="supplementary-material"}). As expected, increasing amounts of TRIM32 in H1299 cells result in decreased steady-state levels of TAp73, in a dose-dependent manner ([Figure 5d](#fig5){ref-type="fig"}, lanes 2 and 3 *versus* lane 1). To determine whether this function was RING-finger-dependent, cells were transfected with HA-TAp73*α* alone or with either TRIM32-WT at different ratios (1 : 1, 1 : 10) or Δ-RING-TRIM32-MUT at the highest ratio ([Figure 5e](#fig5){ref-type="fig"}, lane 4). Although TRIM32-WT decreases TAp73 levels, the catalytic-inactive mutant transfected at the maximum amount does not degrade TAp73 ([Figure 5e](#fig5){ref-type="fig"}, compare lane 4 *versus* lane 1), indicating that TRIM32 degradation of TAp73 occurs, at least in part, in a RING-finger-dependent manner. To further demonstrate that endogenous TRIM32 maintains low endogenous TAp73 protein levels, we inhibited TRIM32 expression in HEK293 cells using two different siRNA oligonucleotides specific for TRIM32 and detected a clear increase in endogenous TAp73*α* protein upon TRIM32 knockdown ([Figure 5f](#fig5){ref-type="fig"}).

To gain insight into the functional consequences of the TRIM32/p73 interaction, we examined the effect of TRIM32 expression on TAp73-mediated transcriptional. We transfected the p21^Cip1^-full-length (FL) promoter-luc reporter plasmid (p21-FL promoter-luc), containing the p53/p73-binding sites, together with TAp73 with or without increasing amounts of TRIM32, or TRIM32 alone. Consistent with TRIM32 degradation of TAp73, increasing amounts of TRIM32 resulted in a significant reduction of TA-p73 transcriptional activation of the p21^Cip1^-FL promoter-luc in neural and non-neural cells ([Figure 5g](#fig5){ref-type="fig"}). Altogether, these results strongly support the idea that TRIM32 targets TAp73 and negatively regulates its protein levels hindering its transcriptional activity.

Discussion
==========

We have identified a new p73 transcriptional target in the context of NPC differentiation and describe a novel regulatory feedback loop between TAp73 and TRIM32. We report, for the first time, that TRIM32 is differentially regulated by p73. Although TAp73 binds and activates TRIM32 promoter, this TAp73-induced TRIM32 expression is efficiently repressed by DNp73. TRIM32 in turn interacts with TAp73 and promotes its ubiquitination and degradation, impairing p73-dependent transcriptional activity.

TRIM32 levels in NPC are regulated by the ratio of TA/DN isoforms present in the cell in each particular moment. Consistent with TAp73 and TRIM32 functions as neural differentiation factors, TRIM32 is expressed at low but detectable levels in NPC under proliferating conditions. Upon induction of differentiation, TAp73 and TRIM32 levels rise sharply within the first hours. Meanwhile, DNp73 expression decreases to almost undetectable level to raise up only at late stages of differentiation.

Functional interaction between p73 and TRIM32 was confirmed by the lower TRIM32 steady-states levels in p73KO NPCs and the impaired TRIM32 expression in VZ/SVZ of p73KO E14.5 embryos, correlating with the reduced amount of newly generated neurons in this region. These data suggest that p73 deficiency results in a deregulation of TRIM32 levels that affects initial neuronal differentiation in the VZ *in vivo*. It is important to point out that TRIM32, although at lower levels, is expressed in p73-deficient cells, *in vivo* as well as *in* *vitro*, indicating that there are other p73-independent factors that support TRIM32 expression. This is consistent with TRIM32 essential role in neural differentiation, but the nature of these factors remains unknown.

TA and DN differential regulation of TRIM32 varies depending on the cell line and is not exclusive of neural-like cells, indicating that p73 transcriptional regulation of TRIM32 is cell context-dependent. This interpretation would be consistent with recent compilation of work regarding p73 function in central nervous system development, which indicates that p73 has a multifunctional role in this process.^[@bib36]^ Although there is strong evidence demonstrating TAp73 induction of neuronal differentiation,^[@bib17],\ [@bib18],\ [@bib37],\ [@bib38]^ recent reports had unequivocally demonstrated p73 requirement, mainly TAp73, in the maintenance of NSC/NPC self-renewal.^[@bib19],\ [@bib20],\ [@bib21],\ [@bib39]^ This contradiction is also reflected in our data. While lower TRIM32 levels are detected in the absence of p73, which is consistent with p73 transcriptional regulation of TRIM32, prematurely differentiating Tuj-1-positive cells in p73KO NPC cultures had enhanced TRIM32 expression triggered by unknown mechanisms, despite the lack of p73. Thus, these data underline the crucial role of TRIM32 in neuronal differentiation and suggest that the appropriated ratios of TA/DNp73 are needed to control not only TRIM32 expression but also to maintain NPC stemness.

Owing to the role of p73 in cellular differentiation and tumor suppression, cells under physiological conditions require mechanisms to keep low-protein steady-state levels. This is achieved through degradation by the 26S proteasome, at least in part, by p73 interaction with E3 ubiquitin ligases like Itch or PIR2.^[@bib14]^ In this regard, we also report a novel regulatory feedback loop between TAp73 and the E3 ligase TRIM32. This negative loop would be regulated by enhanced expression of DNp73, which efficiently inhibits TAp73-mediated TRIM32 expression. It has been proposed that p73 transcriptional activity is linked to its degradation^[@bib40]^ and that regulation of p73 protein stability might be dependent on cell type.^[@bib15]^ Consistently, we observed that TRIM32 overexpression induced TAp73 degradation and impaired its transcriptional activity. TRIM32 efficiency to affect TAp73 transcriptional activity varied depending on the cell line, supporting the role of a cell context factor. This feedback loop is not restricted to the neuronal context, and it may have special relevance in tumor cells. In this regard, TRIM32 has been proposed as a novel oncogene that promotes tumor growth, metastasis and resistance to anticancer drugs.^[@bib30]^ Thus, the p73/TRIM32 loop could be similar to the p53/MDM2/ regulatory node where the Mdm2 oncogene binds to and inhibits the tumor suppressor protein, p53. Nevertheless, TRIM32 function and its interaction with p73 in tumorigenesis need to be further studied.

Materials and Methods
=====================

Mice husbandry and dissection of brain tissues
----------------------------------------------

Animal experiments were conducted in agreement with European (Council Directive 86/609/CEE) and Spanish regulations (RD-1201/2005) for the protection of experimental animals with the appropriate institutional review committee approval. Mice heterozygous for Trp73 on a mixed background C57BL/6 × 129/svJae^[@bib41]^ were backcrossed, at least five times, to C57BL/6 to enrich for C57BL/6 background. To obtain the double Trp73;p53KO mice (DKO), heterozygous animals for Trp73 were crossed with p53KO mice,^[@bib42]^ and then Trp73+/−p53+/− mice were intercrossed to obtain the DKO animals. Mice were genotyped as described before.^[@bib1],\ [@bib41]^

To obtain embryo samples, pregnant females at 14.5 days postcoitum (E14.5d) were euthanized, embryos were extracted and brains were dissected.

To obtain 7 day-old postnatal mice samples, mice were deeply anesthetized by intraperitoneal injection of ketamine/medetomidine and euthanized. Brains were dissected and processed.

Primary culture of neural precursor cells
-----------------------------------------

We utilized primary NS cultures obtained from OBs of Trp73−/− (p73KO from now on) and WT E14.5 embryos.^[@bib21]^ NSCs cultured in the presence of epidermal growth factor (EGF) and basic fibroblast growth factor form NS that preserve NSC self-renewal and multipotency. These mitogenic culture conditions allow NPCs to behave like NSC giving rise to heterogeneous aggregates of NSC and NPC, in which the two populations are indistinguishable. To initiate each independent embryonic culture, the OBs of at least three different E14.5d embryos were dissected out and mechanically dissociated, as described previously.^[@bib43]^ The methods for primary culture of neural precursor cells by the NS assay and differentiation have been described before.^[@bib21]^

Immunostaining and confocal analysis
------------------------------------

Immunocytochemistry was performed as described before^[@bib44]^ using the following antibodies: mouse anti-TRIM32 (1 : 100; Abnova, Taipei City, Taiwan, China), rabbit anti-Tuj-1 (1 : 1000; Covance, Princeton, NJ, USA) and rabbit anti-p-His3 (1 : 100; Chemicon, Billerica, MA, USA). Images were obtained with Nikon EclipseTE2000 confocal microscope. Statistical analysis (Student\'s two-tailed *t*-test) was performed using triplicates from three independent experiments.

RNA isolation and real-time RT-PCR analysis
-------------------------------------------

Total RNA was extracted with TRI reagent (Ambion, Austin, TX, USA) and cDNA was prepared using High Capacity RNA-to-cDNA kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer\'s instructions. P73 and TRIM32 expression was detected by qRT-PCR in a StepOnePlus Real-Time PCR System (Applied Biosystems) using FastStart Universal SYBR Green Master (Roche, Basel, Switzerland). Primers sequences and conditions were described before.^[@bib16],\ [@bib45]^ The expression levels of mRNA were expressed as 2^ΔCt^ and normalized to 18S.

Samples and statistical analyses
--------------------------------

The analyses were performed with data from three independent experiments with at least three embryos of each genotype. Statistical analyses were performed using the Student\'s two-tailed *t*-test (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005), and the S.E. or S.D. of the samples is represented as indicated in each figure legend.

Plasmids and transfection
-------------------------

The cDNAs from human pcDNA3-HA-TAp73*α*, pcDNA3-HA-ΔNp73*α* and pcDNA3-HA-p53 were described previously.^[@bib17]^ Cells were transfected with the indicated plasmids using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) following instructions from the manufacturer, and 24 h after transfection, the cells were harvested and processed.

Immunoprecipitation and ubiquitination assays
---------------------------------------------

Cells treated with 20 *μ*M MG132 (Sigma-Aldrich, St. Louis, MO, USA) were lysed and equal amounts of whole-cell extracts were subjected to immunoprecipitation and immunoblot as described previously.^[@bib49]^ For the ubiquitination studies, a modified lysis method was used to preserve ubiquitin-modified forms as described in Watson and Irwin.^[@bib46]^

Monoclonal antibodies ER15 anti-p73^[@bib47]^ and 12CA5 anti-HA tag (Roche) were used in the immunoprecipitations.

Western blot analysis
---------------------

Brains of 14.5 days embryos were homogenized, lysated and immunoblots were performed as described before.^[@bib17]^ The immunoblots were incubated with the following primary antibodies: rabbit anti-TRIM32 (1 : 1000 (ref. 26), rabbit anti-ERK 2 (1 : 10 000; Santa Cruz Biotechnology, Dallas, TX, USA), rabbit BL906 anti-p73 (1 : 500; Bethyl Laboratories, Montgomery, TX, USA) or rabbit 2301 anti-p73 (0.75 *μ*g/ml (ref. 48)), rabbit A14 anti-myc (1 : 500; Santa Cruz), mouse HA.11 anti-HA tag (1 : 1000; Covance), mouse anti-vinculin (1 : 20 000; Upstate-Millipore, Billerica, MA, USA), mouse anti-T7 (1 : 1000; Novagen, Billerica, MA, USA), followed by the appropriate HRP-conjugated secondary antibodies (Pierce, Waltham, MA, USA). The enhanced chemiluminescence was detected with Super Signal West-Pico Chemiluminiscent Substrate (Pierce), followed by the appropriated HRP-coupled secondary antibodies (Pierce).

Cloning of the human TRIM32 promoter and generation of a deletion mutant
------------------------------------------------------------------------

Genomic DNA was isolated from human keratinocytes and a fragment of the TRIM32 promoter was PCR-amplified. Primers were designed according to the sequence in the genome databases (ENSEMBL Gene ID: ENSG00000119401). Primer sequences are indicated in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}. PCR amplification conditions are available upon request. The amplified fragment spans the region from −1351 to +270, and contains the p53 consensus binding site identified in the proximal promoter (−115 to −84), exon 1 and 218 bp from intron 1.The 1.6-kb PCR product was cloned using the TOPO TA Cloning kit (Invitrogen, Carlsbad, CA, USA). Afterwards, it was inserted as a *Hind*III--*Xho*I fragment into the pGL3-basic luciferase reporter vector (hTRIM32-luc promoter plasmid). Promoter sequence identity was confirmed before and after cloning into the reporter plasmid.

For generating mut-hTRIM32-luc promoter plasmid, the region spanning from −367 to −59, containing the putative p73-binding site, was deleted. A PCR with primers excluding this region was performed using hTRIM32-luc promoter plasmid as template. PCR product ends were polished by T4 DNA polymerase treatment and DNA was re-ligated. The deletion was confirmed by sequencing.

Luciferase assay
----------------

Cells (10^5^) were transfected with 0.125 *μ*g of the reporter luciferase pGL3-hTRIM32-luc or p21^Cip1^-FL promoter-luc plus 0.0625 *μ*g pRLNull and 0.2--0.6 *μ*g of the indicated expression vectors, using Lipofectamine 2000 (Life Technologies) following the manufacturer\'s protocol. Cellular extracts were prepared 24 h after transfection as described before.^[@bib17]^ Measurements were taken in a Berthold\'s luminometer and normalized by the values of the *Renilla* luciferase of the same sample.

siRNA knockdown
---------------

siRNA transfection was performed as described previously.^[@bib7],\ [@bib49]^ Briefly, oligonucleotides (Dharmacon, Lafayatte, CO, USA) at a final concentration of 75 nM were transfected with oligofectamine (Invitrogen) according to the manufacturer\'s instructions. Oligonucleotide sequences for TRIM32 knockdown were as follows: si-TRIM32 1298: 5′-CAGTCAAGGTGAAGTACTA-3′ and si-TRIM32 2074: 5′-GCATCAAGATCTACAGCTA-3′. siGENOME RISC-Free Control siRNA (Dharmacon) was used as the negative control. Anti-p73 siRNA oligos has been described previously.^[@bib7]^

Chromatin immunoprecipitation
-----------------------------

For the ChIPs, N2a cells were transfected with expression constructs for HA-tagged TAp73, DNp73 or EGFP (negative control). Cells were lysed 48 h after transfection, and after crosslinking, the chromatin was precipitated with an anti-HA antibody (Roche). In addition, endogenous p73 was precipitated from untransfected cells with an anti-p73 antibody (Santa Cruz). The complete ChIP was conducted with the HighCell\# ChIP kit (Diagenode, Denville, NJ, USA) according to the manufacturer\'s instructions. To investigate binding to the TRIM32 promoter, precipitated chromatin was used as a template in a PCR reaction with specific primers for TRIM32 promoter (primers were designed to amplify the predicted p73-binding sites).

An *in silico* prediction of p53REs within the human TRIM32 locus was performed with the p53FamTaG database.^[@bib34]^

Immunohistochemistry of free-floating sections
----------------------------------------------

Brains were fixed overnight at 4 °C in 4% PFA in phosphate-buffered saline. Sections of 40 *μ*m were prepared using a vibratome (Leica, Wetzlar, Germany) and blocked for at least 1 h in TBS (0.1 M Tris,150 mM NaCl, pH 7.4) containing 0.5% Triton X-100, 0.1% Na-Azide, 0.1% Na-Citrate and 5% normal goat serum. Immunostainings were performed by incubation of the sections with primary antibodies diluted in the blocking solution for 48 h at 4 °C on a shaker, followed by incubation with the secondary antibody diluted in the blocking solution for 2 h at room temperature. Finally, sections were mounted in AquaMount (DAKO, Glostrup, Denmark). Images were collected by confocal microscopy using ZEN software (Zeiss, Jena, Germany); image analysis was performed with the ZEN software, Adobe Photoshop (San Jose, CA, USA), Image J software (Bethesda, MD, USA) and Imaris software (Zurich, Switzerland).
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NSC

:   neural stem cell

NPC
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MEF
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![P73 expression modulates TRIM32 levels. (**a** and **b**) Quantification of TRIM32 expression level by qRT-PCR analysis upon transfection with the indicated expression vectors in C17.2 (**a**) and N2a (**b**) cell lines. (**c**) Confocal microscopy images of WT NSs after 3 DIV-PM immunostained with antibodies against TRIM32 and TAp73. (**d** and **e**) qRT-PCR (**d**) and western blot analysis (**e**) of TRIM32 levels in NS cultures after 4 DIV-PM. Analysis was performed with data from three independent experiments with at least three embryos of each genotype (mean±standard deviation media (S.D.M.); \**P*\<0.05, \*\*\**P*\<0.005)](cddis2013224f1){#fig1}

![P73 differentially regulates TRIM32 expression at the transcriptional level. (**a**--**d**) Transcriptional analysis with the reporter vector hTRIM32-luc (**a**, **c** and **d**) or mut-hTRIM32-luc (**b**) co-transfected with the indicated expression vectors in C17.2 (**a**), HCT116 (**b**) or p73KO/p53KO (DKO) MEFs (**c** and **d**) cells. Co-transfection of TA/DNp73 in (**d**) ranges from 1 : 0.6 to 1 : 2. (**e**) ChIP assay. DNA agarose gel of PCRs with primers spanning the putative p73-binding sides at positions −10 to −41 and −57 to −79 are shown. As templates immunoprecipitated chromatin was used. N2a cells were transfected either with expression constructs for hemagglutinin (HA)-TAp73 (lane 1), HA-DNp73 (lane 2), enhanced green fluorescent protein (EGFP) (mock control) (lane 3) or were left untransfected (lane 4). Chromatin was precipitated with an anti-HA antibody (lanes 1--3) or an anti-p73 antibody (lane 4). Association with the TRIM32 promoter is shown by PCR with primers specific for p73-binding site. The analyses were performed with data from at least three independent experiments (mean±S.D.M; \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005)](cddis2013224f2){#fig2}

![P73 deficiency results in lower TRIM32 levels *in vitro* and *in vivo*. (**a**--**c**) NS cultures from p73KO E14.4 or WT E14.4 were analyzed after different DIV cultured under differentiating conditions (DIV-PM). (**a** and **b**) Quantitative analysis of TAp73 (black bars), DNp73 (dark gray bars) and TRIM32 (light gray bars) expression kinetics performed by qRT-PCR. (**c**) Confocal microscopy images of NSs after 1 DIV-DM, immunostained with antibodies against TRIM32 and the neuronal marker Tuj1. Blue arrows indicated cells with TRIM32 nuclear staining and Tuji-positive cell with long neurite extensions. Analysis was performed with data from three independent experiments with at least three embryos of each genotype (mean±standard error media (S.E.M.); \**P*\<0.05, \*\**P*\<0.01](cddis2013224f3){#fig3}

![TRIM32 expression levels are reduced in the brain of p73KO E14.5 mice. (**a**) Quantitative analysis of TRIM32 expression in E14.5 mice brains. (**b**--**d**) Immunostainings of brain sections from WT and p73KO mice labeled with the indicated antibodies and quantification of the thickness of the complete cortex (**c**) as well as the thickness of the TuJ1-positive cortical plate (**d**) based on the pictures shown in (**b**) (mean±S.E.M.). (**e** and **f**) Immunostainings of brain sections from WT and p73KO mice labeled with and anti-TRIM32 or TuJ-1 antibody are shown. Based on these pictures, the amount of TuJ1-positive cells in the VZ/SVZ was quantified (mean±S.E.M., \*\**P*\<0.01, \*\*\**P*\<0.005)](cddis2013224f4){#fig4}

![TRIM32 interacts and promotes p73 ubiquitination and degradation, impairing TAp73 transcriptional activity. (**a**) HEK293 cells were transfected with plasmids encoding myc-TRIM32 and hemagglutinin (HA)-TAp73*α*, and treated with MG132 (20 *μ*M) for 6 h. Equal amounts of whole-cell extracts were immunoprecipitated with anti-HA (12CA5) antibody, resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted (IB) with anti-myc antibody. The membrane was then stripped and reprobed with anti-HA (Y-11) antibody. (**b**) HEK293 cells were transfected with plasmid encoding myc-TRIM32 and treated with MG132 (20 *μ*M) for 6 h. Equal amounts of whole-cell extracts were immunoprecipitated with control or anti-p73 (ER-15) antibody, resolved by SDS-PAGE and immunoblotted with anti-myc antibody. The membrane was then stripped and reprobed with anti-p73 (BL906) antibody. (**c**) HEK293 cells were transfected with plasmids encoding the indicated proteins and treated with MG132 (20 *μ*M) for 6 h. Equal amounts of whole-cell extracts were immunoprecipitated with anti-p73 (ER-15) antibody, resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (**d** and **e**) H1299 cells were transfected with constant amounts of plasmid encoding TAp73*α*, increasing amounts of plasmid encoding TRIM32 (p73/TRIM32 ratio=1 : 1, 1 : 10) and plasmid encoding MDM2 or ΔRING-TRIM32 (ratio=1 : 10). (**f**) HEK293 cells were transfected with two different small interfering (si)RNA oligonucleotides specific for TRIM32, or control oligonucleotides. Equal amounts of whole-cell extracts were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. Equal amounts of whole-cell extracts were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (**g**) Transcriptional analysis with the reporter vector p21^Cip1^-FL-luc co-transfected with TAp73 alone or together with TRIM32 in a range from 1 : 0.6 to 1 : 2 or TRIM32 alone in HCT116 (left panel) or C17.2 (right panel) cells. Statistical analysis was performed with data from three independent experiments with at least three embryos of each genotype (mean±S.E.M.; \*\**P*\<0.01)](cddis2013224f5){#fig5}
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